NDA 022145 · Msd Sub Merck
Isentress Hd
Raltegravir Potassium · Oral
NovelAccelerated approvalPriority reviewLast checked: Nov 19, 2026Latest source record: May 18, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Oct 12, 2007
Approved uses
14
Original approval plus efficacy supplements
Registered trials
271
69 Phase 3, 4 recruiting
FAERS reports
16,486
13,706 serious, 1,641 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 16, 2026.
Adult Patients: ISENTRESS and ISENTRESS HD are human immunodeficiency virus integrase strand transfer inhibitors (HIV-1 INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adult patients ( 1 ). Pediatric Patients: ISENTRESS is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients weighing at least 2 kg ( 1 ). ISENTRESS HD is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients weighing at least 40 kg ( 1 ). Adult Patients: ISENTRESS ® and ISENTRESS ® HD are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients. Pediatric Patients: ISENTRESS is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients weighing at least 2 kg. ISENTRESS HD is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients weighing at least 40 kg.
Mechanism: Raltegravir is an HIV-1 antiviral drug [see Microbiology (12.4) ] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 14, 2020 Supplement 42 · Efficacy LabelLetter
- Mar 5, 2018 Supplement 38 · Efficacy LabelLetter
- Nov 22, 2017 Supplement 37 · Efficacy · priority review LabelLetter
- May 26, 2017 Supplement 36 · Efficacy LabelLetterPediatric CDTL Review
- Dec 20, 2013 Supplement 31 · Efficacy · priority review LabelLetter
- Jun 28, 2013 Supplement 27 · Efficacy LetterLabel
- Apr 18, 2012 Supplement 23 · Efficacy LetterLabel
- Mar 28, 2012 Supplement 21 · Efficacy LabelLetter
- Dec 21, 2011 Supplement 22 · Efficacy · priority review LabelPediatric Medical ReviewPediatric Clinical Pharmacology Review
- Jun 29, 2010 Supplement 12 · Efficacy LetterLabel
- Jun 29, 2010 Supplement 11 · Efficacy LabelLetter
- Jul 8, 2009 Supplement 4 · Efficacy LabelReviewLetter
- Jan 29, 2009 Supplement 1 · Efficacy LabelLetterLetter
- Oct 12, 2007 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalReviewPediatric Written RequestPediatric Amendment 1
2 products under this application
- ISENTRESS HD · RALTEGRAVIR POTASSIUM EQ 600MG BASE · TABLET, ORAL · Prescription · TE AB
- ISENTRESS · RALTEGRAVIR POTASSIUM EQ 400MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Raltegravir" as an intervention, any sponsor and status, largest first.
- Comparative Study of Three NNRTI-Sparing HAART RegimensPivotal-lookingCompleted
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsResearch network
NCT00811954 · 1,814 participants · Start May 2009 · Primary completion Jun 2013
Drug: Emtricitabine/tenofovir disoproxil fumarate; Raltegravir and 3 more · For: HIV Infection
Sites: Birmingham, Alabama; Long Beach, California; Los Angeles, California · 57 sites in all
- Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral TherapyPivotal-lookingCompleted
Anna Griffiths, MRCGovernment (non-federal)
NCT01825031 · 1,805 participants · Start Jun 2013 · Primary completion Mar 2016
Drug: Raltegravir; Fluconazole and 3 more · For: Human Immunodeficiency Virus
Sites: Eldoret, Kenya; Kilifi, Kenya; Blantyre, Malawi · 8 sites in all
- IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum WomenPivotal-lookingCompleted
International Maternal Pediatric Adolescent AIDS Clinical Trials GroupResearch network
NCT00955968 · 1,653 participants · Start Jan 1, 2010 · Primary completion Aug 31, 2016
Drug: Highly active antiretroviral therapy (HAART) · For: HIV Infection
Sites: Alhambra, California; Los Angeles, California; San Diego, California · 50 sites in all
- Europe-Africa Research Network for Evaluation of Second-line TherapyPivotal-lookingCompleted
Justine BolesGovernment (non-federal)
NCT00988039 · 1,277 participants · Start Mar 2010 · Primary completion Jan 2014
Drug: Aluvia + 2NRTIs; Aluvia + raltegravir and 1 more · For: Human Immunodeficiency Virus; HIV
Sites: Eldoret, Kenya; Blantyre, Malawi; Mzuzu, Malawi · 14 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT02140255 · 1,120 participants (planned) · Start Jan 23, 2015 · Primary completion Jan 31, 2028
Drug: Nucleoside Reverse Transcriptase Inhibitors (NRTIs); Nevirapine (NVP) and 5 more · For: HIV Infection
Sites: La Jolla, California; Los Angeles, California; Aurora, Colorado · 47 sites in all
- A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice DailyPivotal-lookingCompleted
ViiV HealthcareGSK (GSK)
NCT01227824 · 828 participants · Start Oct 19, 2010 · Primary completion Feb 6, 2012
Drug: GSK1349572 (dolutegravir); raltegravir · For: Infection, Human Immunodeficiency Virus I
Sites: Phoenix, Arizona; Little Rock, Arkansas; Long Beach, California · 101 sites in all
- Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02131233 · 802 participants · Start May 23, 2014 · Primary completion Dec 21, 2015
Drug: Reformulated Raltegravir; Raltegravir and 3 more · For: HIV Infection
- Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve SubjectsPivotal-lookingCompleted
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
NCT01066962 · 800 participants · Start Aug 2010 · Primary completion Oct 2013
Drug: darunavir/ritonavir QD + raltegravir BID; darunavir/r QD + tenofovir/emtricitabine QD (fixed dose combination) · For: HIV Infections
Sites: Vienna, Austria; Antwerp, Belgium; Brussels, Belgium · 77 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug interaction1,216
- foetal exposure during pregnancy1,100
- depression1,018
- anxiety965
- pain917
- emotional distress789
- maternal exposure during pregnancy750
- exposure during pregnancy744
- anhedonia708
- virologic failure587
- renal failure558
- chronic kidney disease548
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2007 | 17 |
| 2008 | 449 |
| 2009 | 648 |
| 2010 | 739 |
| 2011 | 611 |
| 2012 | 1,020 |
| 2013 | 936 |
| 2014 | 1,051 |
| 2015 | 1,147 |
| 2016 | 1,312 |
| 2017 | 1,044 |
| 2018 | 1,442 |
| 2019 | 1,491 |
| 2020 | 1,204 |
| 2021 | 1,052 |
| 2022 | 891 |
| 2023 | 695 |
| 2024 | 318 |
| 2025 | 256 |
| 2026 | 162 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Isentress (Raltegravir Potassium)
2024 spending
$113M
Beneficiaries
7,188
53,765 claims
Per beneficiary
$15,684
$33.14 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $188,251,438 |
| 2021 | $164,360,689 |
| 2022 | $146,220,371 |
| 2023 | $130,537,595 |
| 2024 | $112,736,203 |
Part D: Isentress Hd (Raltegravir Potassium)
2024 spending
$23.0M
Beneficiaries
1,228
11,049 claims
Per beneficiary
$18,746
$33.08 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $30,536,040 |
| 2021 | $29,368,766 |
| 2022 | $28,930,429 |
| 2023 | $26,641,375 |
| 2024 | $23,019,649 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
Naggie S, Cooper C, Saag M, et al. · N Engl J Med 2015 · Clinical Trial, Phase III, Multicenter Study
- Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens.
Leonard MA, Cindi Z, Bradford Y, et al. · Clin Infect Dis 2021 · Observational Study, Randomized Controlled Trial
- Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C).
Hernández-Novoa B, Moreno A, Pérez-Elías MJ, et al. · J Antimicrob Chemother 2014 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Different impact of raltegravir versus efavirenz on CD4/CD8 ratio recovery in HIV-infected patients.
Serrano-Villar S, Zhou Y, Rodgers AJ, et al. · J Antimicrob Chemother 2017 · Clinical Trial, Phase III, Comparative Study
- Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis.
Messiaen P, Wensing AM, Fun A, et al. · PLoS One 2013 · Meta-Analysis, Systematic Review
- The effect of raltegravir on the glucuronidation of lamotrigine.
van Luin M, Colbers A, Verwey-van Wissen CP, et al. · J Clin Pharmacol 2009 · Clinical Trial, Phase I, Randomized Controlled Trial
Sponsor: Merck & Co. · Also marketed as Isentress
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.